Fiorenza Barraco

机构：Hôpital Lyon Sud · ORCID：0000-0001-7919-6736

发表论文 166 篇 · 总被引 2744 次 · h-index 26

代表论文

• Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia (2022 · New England Journal of Medicine · 被引 322)
• Therapeutic options in VEXAS syndrome: insights from a retrospective series (2021 · Blood · 被引 287)
• Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study (2022 · Blood · 被引 215)
• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study (2023 · The Lancet · 被引 200)
• Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience (2021 · Blood Advances · 被引 147)
• Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial (2023 · The Lancet Haematology · 被引 93)